Search Immortality Topics:

Page 5«..4567..1020..»


Category Archives: Stem Cell Therapy

Combining cell types may lead to improved cardiac cell therapy … – University of Wisconsin-Madison

Human heart cells (green-and-red-striped bands in the lower half of the image) grafted into a nonhuman primate heart aside native heart cells (striped red without green). Mixing in the cells that line arteries with heart muscle has improved the grafts. Image By: Yu-Che Cheng

Researchers at the University of WisconsinMadison and Academia Sinica of Taiwan have harnessed a combination of lab-grown cells to regenerate damaged heart muscle.

The study, published in Circulation which addresses major challenges of using heart muscle cells, called cardiomyocytes, grown from stem cells takes a crucial step toward future clinical applications.

Previous research has shown that transplanting cardiomyocytes made from induced pluripotent stem cells (iPSC) can replace muscle in the hearts of mammals. Researchers have struggled to bring the treatment to the clinic, in part because the implanted cells havent developed enough life-sustaining blood vessels to survive very long.

The new study confronted that challenge by combining the lab-grown cardiomyocytes with stem-cell-derived endothelial cells the cells that line blood. The combination therapy also holds promise for tackling arrhythmia, another significant obstacle in heart regeneration with stem-cell-derived cardiomyocytes.

Our findings suggest that human iPSC-derived endothelial cells can effectively augment the remuscularization of the heart by iPSC-derived cardiomyocytes, offering a promising avenue for future clinical applications, says Patrick Hsieh, a researcher with Academia Sinicas Institute of Biomedical Sciences who conducted the study while working as a visiting professor at the UWMadisonStem Cell & Regenerative Medicine Center.

Timothy Kamp

Hsieh and study lead author Yu-Che Cheng collaborated with Tim Kamp, who serves as director of the Stem Cell & Regenerative Medicine Center, as well as a team of researchers at UWMadison and the Wisconsin National Primate Research Center, to examine the therapeutic effect of co-transplantation in mice and non-human primates undergoing a heart attack.

The main advantage of iPSCs is their ability to be differentiated into many types of cells and serve as a valuable resource for cell therapy, says Cheng, who is a project manager at Academia Sinica. In this study, we generated billions of endothelial cells and cardiomyocytes from the same iPSCs line to inject into mice and non-human primates.

The simple idea of the project was to enhance blood flow and promote survival of iPSC-cardiomyocytes using blood vessel-forming endothelial cells, Kamp says. But the reality of generating the optimal cell preparations followed by precise delivery to the heart reflects tremendous effort by an international team of collaborators.

The team would like to conduct further studies to refine their cell transplantation protocols and assess long-term safety and efficacy. Promising results, Hsieh believes, would lead to clinical trials with human patients with heart disease, a leading cause of death around the world.

As a cardiac surgeon now focusing on translational research, the most exciting aspect of this research is the potential to make a meaningful impact on the treatment of heart disease, Hsieh says. Witnessing the significant improvements in cardiac function and tissue regeneration resulting from our combined cell therapy approach is both inspiring and promising for the future of cardiovascular medicine.

This research was supported by grants from the Ministry of Science and Technology, Taiwan (111-2321-B-001-012, 111-2740-B-001-003, 110-2320-B-001-023), National Health Research Institutes (EX111-10907SI), U.S. National Academy of Medicine and Academia Sinica (AS-HLGC-109-05), National Institutes of Health (U01HL134764 and UL1TR002373) and the National Science Foundation (EEC-1648035).

Read this article:
Combining cell types may lead to improved cardiac cell therapy ... - University of Wisconsin-Madison

Posted in Stem Cell Therapy | Comments Off on Combining cell types may lead to improved cardiac cell therapy … – University of Wisconsin-Madison

Stem Cell Transplantation Delivers in Treating Blood Cancer – Targeted Oncology

Over the past few decades, the landscape of blood cancer treatment has undergone a remarkable transformation. We have a deeper understanding of the molecular and genetic basis of blood cancers, and there have been rapid developments in the realm of immunotherapy and targeted therapies.

Among the most revolutionary therapies for hematologic malignancies is stem cell transplantation, which had its beginnings in the 1950s. Allogeneic transplant is, today, a curative therapy for a variety of blood cancers, including many cases of acute monocytic leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes.

Its crucial that we make the next leap in the transformation of care for our patients, and to do so we must continue to remain focused on key aspects that greatly affect outcomes, including:

Conditioning regimens to reduce pre-transplantation toxicities and complications

Graft-versus-host disease (GVHD) risk to lessen the chance of a life-threatening complication through the use of graft manipulation or posttransplantation cytotoxin administration

Relapse to enhance relapse management by integrating maintenance treatments, early management at the first signs of minimal residual disease or of relapse, bolstering the grafts ability to recognize and attack residual malignant cells and potential infusions of CAR T cells derived from the original or from a third-party donor as an approach to prevent or treat relapse post stem cell transplant

Infectious complications to reduce the risk of viral infections and reactivations, using antimicrobial prophylaxis, by continuing close monitoring and administration of anti-viral specific immune cells

A plethora of research in these areas is already leading and will continue to lead to changes that impact outcomes. For example, OReilly et al,1 determined that consistent engraftment and lower incidences of acute and chronic GVHD occurred when allogeneic hematopoietic cell transplantation (HCT) depleted of T-cells were administered after myeloablative chemotherapy in patients.1 The work of Kosuri et al, in identifying a variety of cardiovascular, hematologic, and renal toxicities that contribute to morbidity and mortality in the first year of treatment in adults who undergo myeloablative allogeneic HCT with ex vivo CD34+ selection, helped establish a benchmark for toxicity reduction.2

Relapse continues to be of high concern, as well, and at the European Hematology Association 2023 meeting in June, we presented results of study VBP101 (NCT04849910), a first-in-human clinical trial utilizing CD34+ selected allografts with gene-edited CD33-negative hematopoietic stem cells from HLA matched related or unrelated donors for patients with AML. The VBP101 trial is a phase 1/2a multicenter study looking at the combination of trem-cel and escalating doses of gemtuzumab ozogamicin (Mylotarg). Part 1 of the trial evaluates the safety of escalating doses of gemtuzumab ozogamicin and part 2 increases the number of participants.3

Our efforts to tailor treatment to the individual must also remain a priority. Just 5 years ago, we treated all patients with AML as a relatively homogeneous group. We now understand that there are differences based on molecular profiling. The research of Stone et al revealed that standard chemotherapy with daunorubicin and cytarabine plus the multitargeted kinase inhibitor midostaurin (Rydapt) prolonged overall and event-free survival.4

It is through collaboration that we can achieve the most significant gains. Please join us at the Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, March 8 to 9, 2024, at the JW Marriott Brickell in Florida.

Originally posted here:
Stem Cell Transplantation Delivers in Treating Blood Cancer - Targeted Oncology

Posted in Stem Cell Therapy | Comments Off on Stem Cell Transplantation Delivers in Treating Blood Cancer – Targeted Oncology

Tract Bio Announces Publication in American Journal of Respiratory … – BioSpace

Breakthrough stem cell discovery platform, stemECHO, clones pathogenic disease-causing stem cells, identifying druggable targets for cancer and inflammatory disease

BOSTON, Nov. 1, 2023 /PRNewswire/ -- Tract Bio, a biotechnology company discovering and developing novel therapies for cancer and inflammatory disease, today announced the publication of a research article in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) highlighting the stem cell variants driving chronic lung inflammation in modulator-treated cystic fibrosis patients (CFTR modulators).

The article, "Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lung Is Not Resolved by CFTR Modulators," appeared in theNovember 2023 printededition of the peer-reviewed journal. In the publication, study authors suggest that the emergence of three proinflammatory stem cell variants in the cystic fibrosis (CF) lung may contribute to the persistence of lung inflammation in CF patients with advanced disease undergoing CFTR modulator therapy.

"Lung neutrophils and inflammatory cytokines remain high in modulator-treated CF patients with established lung disease, emphasizing the importance of identifying and addressing the underlying cause of inflammation in CF lungs," said Dr. Frank McKeon, Ph.D., Interim Chief Scientific Officer of Tract Bio. "We identified five stem cell variants common to lungs of patients with advanced CF, three of which exhibit hyperinflammatory gene expression profiles and neutrophilic inflammation. Proinflammatory functions of these variants were unalleviated by genetic or pharmacological restoration of CFTR activity, reflecting the limitations of CFTR modulator drugs to mitigate this inflammation."

"This research demonstrates the unprecedented potential opportunity our proprietary drug discovery platform provides for identification of novel therapies that selectively target the underlying cause of disease," said Richard Russell, Chief Executive Officer and Board Member of Tract Bio. "Our mission in drug discovery is to identify pathogenic stem cells that play a significant role in the most aggressive forms of cancer and inflammation and to develop novel therapies that target them. We have already identified lead compounds that are effective in preclinical models for a wide range of cancers and inflammatory diseases. We aim to eliminate the cause of the condition instead of mitigating the symptoms."

"This publication underscores the urgent need for additional research efforts and development of novel therapies for CF," said Wa Xian, Ph.D., Professor of Biology and Biochemistry at the University of Houston Stem Cell Center. "While CFTR modulators are proven to be an effective therapy for patents with CF, like many currently available treatment options, it does not address all aspects of the disease. The powerful technology that Tract has developed to capture and clone individual stem cells represents an innovative and potentially valuable approach to CF drug discovery and development."

About Tract Bio Tract Bio is a biotechnology company discovering and developing novel therapies to transform treatment of cancer and inflammatory disease. The Company's breakthrough stem cell discovery platform, stemECHO, allows for reliable, high-volume generation of pure stem cell libraries in their ground-state while preserving the functional, genetic and epigenetic integrity of the original stem cell. The stemECHOplatform has identified disease-associated stem cells in cancer and inflammatory diseases, including potential treatments for esophageal adenocarcinoma, lung, pancreatic, ovarian and gastric cancer, as well as COPD, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis and Crohn's Disease.Tract is advancing TP-101, a novel drug combination identified using stemECHO that targets a common mechanism among disease-associated stem cells in cancer. The Company is also developing novel therapies for inflammatory diseases.

Contacts: Investors/Media Argot Partners tract@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tract-bio-announces-publication-in-american-journal-of-respiratory-and-critical-care-medicine-highlighting-stem-cell-variants-driving-lung-inflammation-in-modulator-treated-cystic-fibrosis-patients-301973486.html

SOURCE Tract Bio

The rest is here:
Tract Bio Announces Publication in American Journal of Respiratory ... - BioSpace

Posted in Stem Cell Therapy | Comments Off on Tract Bio Announces Publication in American Journal of Respiratory … – BioSpace

Cell Therapy Market to Witness Exponential Growth by 2031 … – Argyle Report

SAN FRANCISCO, Nov. 01, 2023 /Argylereport/ The Global Cell Therapy Market 2023 Research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Cell Therapy market report is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analysed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report also focuses on Cell Therapy major leading industry players of Cell Therapy market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. This report focuses on Cell Therapy Market Trend, volume and value at Cell Therapy level, regional level and company level. From a Cell Therapy perspective, this report represents overall Cell Therapy Market Size by analyzing historical data and future prospect.

Request a Sample Report of Cell Therapy Market @ https://marketintelx.com/sample_request/3988

Some of the Top companies influencing this Market include:

ALLOSOURCE, OSIRIS THERAPEUTICS, INC., HOLOSTEM TERAPIE AVANZATE SRL, MESOBLAST LTD, JCR PHARMACEUTICALS CO., LTD., KOLON TISSUEGENE, INC., NUVASIVE, INC., STEMEDICA CELL TECHNOLOGIES, INC, MEDIPOST CO., LTD., CELLS FOR CELLS

Market Segmentation:

By Cell Type Stem Cell Bone Marrow Blood Umbilical Cord-Derived Adipose-Derived Stem Cell Others (placenta, and nonspecific cells) Non-stem Cell

By Therapy Type Autologous Allogeneic

By Therapeutic Area Malignancies Musculoskeletal Disorders Autoimmune Disorders Dermatology Others

By End User Hospitals & Clinics Academic & Research Institutes

The cost analysis of the Global Cell Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report then includes an assessment of various drivers, technological innovations, upcoming technologies, opportunities, market risks, restraints, market barriers, challenges, trends, competitive landscape, and segments which gives an exact picture of the growth of the global Cell Therapy market. The report offers different facts and figures for a basic understanding of the business. The study then strategically profiles the key players and analyzes their development, mergers and acquisition, and the R&D investment created by the competitors.

Critical Features Of The Report:

The report provides regional-level analysis for regions covering:

The report helps global Cell Therapy market players build future business master plans and discover global competition. Different market forecasts related to market size, production, revenue, consumption, CAGR, gross margin, price, and other key factors are provided for 2023 to 2030 time-period. In addition, the report includes regional analysis and market dynamics. The development scope, feasibility study, market concentration, and maturity analysis are elaborated in this report.

Chapters Covered in Market Report Are as Follow:

Buy Exclusive Report @ https://marketintelx.com/checkout/?currency=USD&type=single_user_license&report_id=3988 If you have any special requirements, please let us know and we will offer you the report at a customized price.

Contact us

Sarah Ivans | Business Development

Phone: +1 805 751 5035

Phone: +44 151 528 9267

Email: [emailprotected]

Website: http://www.marketintelx.com

Go here to see the original:
Cell Therapy Market to Witness Exponential Growth by 2031 ... - Argyle Report

Posted in Stem Cell Therapy | Comments Off on Cell Therapy Market to Witness Exponential Growth by 2031 … – Argyle Report

Dr Murthy on the Use of CAR T-Cell Therapy in Elderly or Frail … – OncLive

Hemant S. Murthy, MD, hematologist/oncologist, physician, Mayo Clinic, discusses the evolving use of CAR T-cell therapy for elderly or frail patient populations withrelapsed/refractory B-cell lymphomas.

Murthy begins by stating that current registry studies, including a large study based in Germany, have demonstrated the feasibility of administering CAR T-cell therapy to elderly patients with B-cell lymphomas. These studies did not reveal significant variation in the frequency of treatment-related cytokine release syndrome based on age in patients with B-cell lymphomas who were treated with CAR T-cell therapy. However, elderly patients tended to experience more immune effector cellassociated neurotoxicity syndrome.

To elucidate whether CAR T-cell therapy is a viable treatment alternative for patients with aggressive relapsed/refractory B-cell lymphomas who are deemed ineligible for autologous stem cell transplant (ASCT), the open-label, phase 2 ALYCANTE trial (NCT04531046) evaluated the efficacy and safety of axicabtagene ciloleucel (Yescarta; axi-cel) in the second-line setting, Murthy details. ASCT ineligibility was largely determined by age, prior treatment with ASCT, and a Hematopoietic Cell Transplantationspecific Comorbidity Index score of 3 or higher, he expands. The ALYCANTE trial employed a broad set of exclusion criteria. This included pulmonary complications, cardiac issues, pleural effusions, and hepatitis, Murthy states.

Results demonstrated that axi-cel produced a complete metabolic response (CMR) rate of 71% at 3 months vs an expected 12% CMR rate with the standard of care based on historical controls, meeting the study's primary end point (n=44; 95% CI, 58.1%81.8%). At 6 months, 59.7% of patients (n=37) who received axi-cel continued to exhibit a CMR. Additionally, patients experienced a treatment-related mortality rate of 9.7% with axi-cel, which was higher than the 1% to 2% rate historically associated with ASCT, Murthy reports.

Although the ALYCANTE trial shows promising results with axi-cel, it also underscores the ongoing challenge of identifying and defining which patients are ineligible for CAR T-cell therapy, Murthy emphasizes. Patient selection remains a work in progress, with ongoing studies aiming to refine this process, Murthy concludes.

See the rest here:
Dr Murthy on the Use of CAR T-Cell Therapy in Elderly or Frail ... - OncLive

Posted in Stem Cell Therapy | Comments Off on Dr Murthy on the Use of CAR T-Cell Therapy in Elderly or Frail … – OncLive

Global Automated and Closed Cell Therapy Processing Systems … – GlobeNewswire

Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Automated and Closed Cell Therapy Processing Systems Market 2023-2030" report has been added to ResearchAndMarkets.com's offering.

The global automated and closed cell therapy processing systems market is on an impressive trajectory, projected to reach USD 3.66 billion by 2030, with a remarkable compound annual growth rate (CAGR) of 18.2% over the forecast period. Market players are investing significantly in automated processes, propelling the development of cell therapy products and driving market expansion.

Key Market Drivers

Market Highlights

In Summary

The automated and closed cell therapy processing systems market is experiencing robust growth, driven by automation, expansion of manufacturing facilities, the versatility of disposable tubing sets and bags, the impact of the COVID-19 pandemic, and the development of diverse therapies. With North America leading the way and strategic collaborations shaping the landscape, the market is set to reach remarkable heights, with a projected value of USD 3.66 billion by 2030.

Key Attributes

Key Topics Covered

Chapter 1. Methodology and Scope Chapter 2. Executive Summary Chapter 3. Automated and Closed Cell Therapy Processing Systems Market Variables, Trends & Scope Chapter 4. Automated and Closed Cell Therapy Processing Systems Market: Workflow Estimates & Trend Analysis Chapter 5. Automated and Closed Cell Therapy Processing Systems Market: Type Estimates & Trend Analysis Chapter 6. Automated and Closed Cell Therapy Processing Systems Market: Scale Estimates & Trend Analysis Chapter 7. Automated and Closed Cell Therapy Processing Systems Market: Regional Estimates & Trend Analysis Chapter 8. Competitive Landscape

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/775biy

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

The rest is here:
Global Automated and Closed Cell Therapy Processing Systems ... - GlobeNewswire

Posted in Stem Cell Therapy | Comments Off on Global Automated and Closed Cell Therapy Processing Systems … – GlobeNewswire